Cargando…

Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery

In the current study, the lipid-shell and polymer-core hybrid nanoparticles (lpNPs) modified by Arg–Gly–Asp(RGD) peptide, loaded with curcumin (Cur), were developed by emulsification-solvent volatilization method. The RGD-modified hybrid nanoparticles (RGD–lpNPs) could overcome the poor water solubi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yinbo, Lin, Dayong, Wu, Fengbo, Guo, Li, He, Gu, Ouyang, Liang, Song, Xiangrong, Huang, Wei, Li, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227178/
https://www.ncbi.nlm.nih.gov/pubmed/25268623
http://dx.doi.org/10.3390/ijms151017565
_version_ 1782343751250739200
author Zhao, Yinbo
Lin, Dayong
Wu, Fengbo
Guo, Li
He, Gu
Ouyang, Liang
Song, Xiangrong
Huang, Wei
Li, Xiang
author_facet Zhao, Yinbo
Lin, Dayong
Wu, Fengbo
Guo, Li
He, Gu
Ouyang, Liang
Song, Xiangrong
Huang, Wei
Li, Xiang
author_sort Zhao, Yinbo
collection PubMed
description In the current study, the lipid-shell and polymer-core hybrid nanoparticles (lpNPs) modified by Arg–Gly–Asp(RGD) peptide, loaded with curcumin (Cur), were developed by emulsification-solvent volatilization method. The RGD-modified hybrid nanoparticles (RGD–lpNPs) could overcome the poor water solubility of Cur to meet the requirement of intravenous administration and tumor active targeting. The obtained optimal RGD-lpNPs, composed of PLGA (poly(lactic-co-glycolic acid))–mPEG (methoxyl poly(ethylene- glycol)), RGD–polyethylene glycol (PEG)–cholesterol (Chol) copolymers and lipids, had good entrapment efficiency, submicron size and negatively neutral surface charge. The core-shell structure of RGD–lpNPs was verified by TEM. Cytotoxicity analysis demonstrated that the RGD–lpNPs encapsulated Cur retained potent anti-tumor effects. Flow cytometry analysis revealed the cellular uptake of Cur encapsulated in the RGD–lpNPs was increased for human umbilical vein endothelial cells (HUVEC). Furthermore, Cur loaded RGD–lpNPs were more effective in inhibiting tumor growth in a subcutaneous B16 melanoma tumor model. The results of immunofluorescent and immunohistochemical studies by Cur loaded RGD–lpNPs therapies indicated that more apoptotic cells, fewer microvessels, and fewer proliferation-positive cells were observed. In conclusion, RGD–lpNPs encapsulating Cur were developed with enhanced anti-tumor activity in melanoma, and Cur loaded RGD–lpNPs represent an excellent tumor targeted formulation of Cur which might be an attractive candidate for cancer therapy.
format Online
Article
Text
id pubmed-4227178
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42271782014-11-12 Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery Zhao, Yinbo Lin, Dayong Wu, Fengbo Guo, Li He, Gu Ouyang, Liang Song, Xiangrong Huang, Wei Li, Xiang Int J Mol Sci Article In the current study, the lipid-shell and polymer-core hybrid nanoparticles (lpNPs) modified by Arg–Gly–Asp(RGD) peptide, loaded with curcumin (Cur), were developed by emulsification-solvent volatilization method. The RGD-modified hybrid nanoparticles (RGD–lpNPs) could overcome the poor water solubility of Cur to meet the requirement of intravenous administration and tumor active targeting. The obtained optimal RGD-lpNPs, composed of PLGA (poly(lactic-co-glycolic acid))–mPEG (methoxyl poly(ethylene- glycol)), RGD–polyethylene glycol (PEG)–cholesterol (Chol) copolymers and lipids, had good entrapment efficiency, submicron size and negatively neutral surface charge. The core-shell structure of RGD–lpNPs was verified by TEM. Cytotoxicity analysis demonstrated that the RGD–lpNPs encapsulated Cur retained potent anti-tumor effects. Flow cytometry analysis revealed the cellular uptake of Cur encapsulated in the RGD–lpNPs was increased for human umbilical vein endothelial cells (HUVEC). Furthermore, Cur loaded RGD–lpNPs were more effective in inhibiting tumor growth in a subcutaneous B16 melanoma tumor model. The results of immunofluorescent and immunohistochemical studies by Cur loaded RGD–lpNPs therapies indicated that more apoptotic cells, fewer microvessels, and fewer proliferation-positive cells were observed. In conclusion, RGD–lpNPs encapsulating Cur were developed with enhanced anti-tumor activity in melanoma, and Cur loaded RGD–lpNPs represent an excellent tumor targeted formulation of Cur which might be an attractive candidate for cancer therapy. MDPI 2014-09-29 /pmc/articles/PMC4227178/ /pubmed/25268623 http://dx.doi.org/10.3390/ijms151017565 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhao, Yinbo
Lin, Dayong
Wu, Fengbo
Guo, Li
He, Gu
Ouyang, Liang
Song, Xiangrong
Huang, Wei
Li, Xiang
Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title_full Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title_fullStr Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title_full_unstemmed Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title_short Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
title_sort discovery and in vivo evaluation of novel rgd-modified lipid-polymer hybrid nanoparticles for targeted drug delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227178/
https://www.ncbi.nlm.nih.gov/pubmed/25268623
http://dx.doi.org/10.3390/ijms151017565
work_keys_str_mv AT zhaoyinbo discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT lindayong discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT wufengbo discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT guoli discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT hegu discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT ouyangliang discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT songxiangrong discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT huangwei discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery
AT lixiang discoveryandinvivoevaluationofnovelrgdmodifiedlipidpolymerhybridnanoparticlesfortargeteddrugdelivery